

- hemoptysis, 1793–1794  
 hemorrhagic cystitis, 1798  
 human antibody infusion reactions, 1796  
 hypersensitivity reactions to antineoplastic drugs, 1798  
 hypocalcemia. *See* Hypocalcemia  
 hypoglycemia, 1794–1795  
 increased intracranial pressure, 1792  
 intestinal obstruction, 1789–1790  
 lactic acidosis, 1794  
 neoplastic meningitis, 1792–1793  
 neutropenic enterocolitis, 488, 1797–1798, 1798f  
 pericardial effusion/tamponade, 474, 1788–1789  
 pneumonia, 488–489, 489t, 1797  
 pneumonitis, 489, 489t, 621–622, 1797  
 pulmonary and intracerebral leukostasis, 1793  
 pulmonary infiltrates, 1797  
 seizures, 1793  
 SIADH. *See* Syndrome of inappropriate antidiuretic hormone (SIADH)  
 spinal cord compression. *See* Spinal cord compression, neoplastic  
 superior vena cava syndrome. *See* Superior vena cava syndrome  
 tumor lysis syndrome. *See* Tumor lysis syndrome  
 urinary obstruction, 1790  
 extent of disease, 470–471  
 fatigue in, 152  
 fever of unknown origin in, 136t, 137t, 138  
 genetic considerations in. *See* Cancer genetics  
 genetic testing in, 101e-6–7, 101e-8f, 450t  
 global burden of, 16  
 global considerations in, 467–468, 490  
 immunization in, 485t, 492  
 incidence of, 467, 467t, 468f, 471t  
 infections in, **484**  
   antibacterial therapy for, 490–491  
   antibiotic prophylaxis for, 492  
   antifungal therapy for, 491  
   antiviral therapy for, 491–492  
   cardiovascular, 489  
   catheter-related, 487, 487t  
   central nervous system, 488, 488t  
   cytokine therapy, 492  
   endocrine, 489  
   febrile neutropenia and, 103e-23, 490, 490f  
   gastrointestinal tract, 487–488, 1797–1798  
   granulocyte transfusions for, 492  
   musculoskeletal, 489–490  
   predisposing factors in, 484–485, 484t, 490  
   prevention of, 492  
   pulmonary, 488–489, 489t, 1797  
   renal-ureteral, 490  
   skin, 76e-12f, 485–487, 486f  
 infectious causes of, 761  
 in inflammatory myopathies, 2196  
 involuntary weight loss in, 275  
 late complications of, 473, **620**, 620t, 624t  
 in low- and middle-income countries, 16, 16f  
 lymphatic vessels of, 102e-15  
 metastasis of, 102e-1t. *See also* Metastatic disease  
 new symptoms in, 472  
 nutritional status of patient, 474  
 obesity and, 415e-6  
 as organ that ignores its niche, 102e-2–3  
 pain in, 473–474  
 pathogenesis of. *See* Cancer cells  
 patient management in, **468**  
 physiologic reserve of patient, 470–471, 472t  
 during pregnancy, **124e-1**  
 prevention of. *See* Cancer prevention  
 prognosis of, 470–471  
 progressive disease, 472  
 recurrent, 473  
 risk factors for, 467, 2725, 2730, 2730t  
 screening for. *See* Cancer screening  
 second malignancy, 103e-4, 623  
   by cancer type, 623  
   chemotherapy-related, 623, 709  
   hormonal therapy-related, 623  
   immunosuppressive therapy-related, 623–624  
   radiation therapy-related, 623, 709  
   in transplant recipient, 928  
 self-renewing capacity of, 89e-4  
 stable disease, 472  
 staging of, 103e-2, 470  
 survivorship issues, 475, 620, 622, 624, 624t  
 treatment of  
   assessing response to, 472–473, 473t  
   biologic therapy. *See* Cancer biologic therapy  
   cancer stem cells as target of, 102e-11  
   chemotherapy. *See* Cancer chemotherapy  
   complementary and alternative medicine, 473  
   complete response to, 472  
   gene therapy, 91e-2f, 91e-3–4, 91e-3t  
   genetic considerations in, 101e-8–9  
   goal of, 103e-2  
   late consequences of, 624t  
   long-term follow-up, 473, 624  
   palliative, 103e-3, 472  
   partial response to, 472  
   planning, 471–472  
   principles of, **103e-1**  
   psychosocial support, 474–475  
   radiation therapy. *See* Radiation therapy  
   salvage treatment plan, 473  
   spectrum of, 103e-1t, 103e-2  
   supportive care, **473**  
   surgical. *See* Cancer surgery  
   tumor growth rates in, 102e-2–3, 103e-2, 103e-3f  
   tumor microenvironment in, 102e-13  
   viruses and, 101e-7  
**Cancer biologic therapy, 103e-20**  
 action and targets of, 103e-5, 103e-5t, 103e-7f  
 adverse effects of, 103e-21  
 antibody-mediated, 103e-20–21  
 antiangiogenic, 102e-15, 102e-16f, 102e-17, 102e-17f, 102e-21t  
 conjugates, 102e-4, 102e-5t, 103e-22  
 immunoregulatory, 102e-5t, 102e-17–18, 102e-18f, 103e-21–22, 103e-21t, 103e-22f  
 tumor-regulatory, 102e-5t, 103e-21, 103e-21t  
 cytokines, 103e-22  
 immune cell-mediated, 102e-17–18, 103e-20  
 ligand receptor-directed constructs, 103e-22  
 principles of, 102e-17–18, 103e-20  
 T cell-mediated, 103e-20  
**Cancer cells**  
 apoptosis in, 102e-1t, 102e-8–10, 102e-9f, 103e-6, 103e-7f  
 autophagy in, 102e-10  
 biology of, **102e-1**  
 cell cycle in, 102e-1–2, 103e-8  
 chromatin structure alterations in, 102e-7–8, 102e-8f  
 evasion of immune system, 102e-1t  
 failure to differentiate, 102e-1t  
 gene expression in, 102e-1t, 102e-7–8, 102e-8f  
 Gompertzian growth curve/kinetics in, 102e-2, 103e-2, 103e-3f  
 induction of differentiation in, 103e-6  
 loss of replicative senescence in, 102e-1t, 102e-3  
 metabolism in, 102e-12–13, 102e-13f  
 mutations in, 101e-8, 102e-1  
 necrosis in, 102e-10  
 oncogene addiction in, 102e-6  
 phenotypic characteristics of, 102e-1t  
 plasticity of, 102e-12  
 resistance of, 102e-12  
 signal transduction pathways in, 102e-3–7, 102e-4f  
 synthetic lethality in, 102e-6f  
 telomerase activation in, 102e-3  
 tissue invasion by, 102e-1t, 102e-10  
 in tumor angiogenesis. *See* Angiogenesis, tumor  
**Cancer chemotherapy, 103e-5. See also specific drugs and cancers**  
 action of, 103e-6–7, 103e-7f  
 adjuvant, 103e-7  
 cell/tumor response to, 103e-6–7  
 complete response to, 103e-5  
 complications of, 472, 489  
   cardiovascular, 270e-21–22  
   neurologic, 607, 607t  
   neuropathies, 2686, 2686t  
 curability of cancers with, 103e-6–7, 103e-8t  
 cytotoxic  
   antimetabolites, 103e-10–11t, 103e-13–14  
   antimitotic agents, 103e-11–12t, 103e-14–15  
   antitumor antibiotics, 103e-9–10t, 103e-13  
   DNA-interactive agents, 103e-8, 103e-9t, 103e-12  
   topoisomerase inhibitors, 103e-9–10t, 103e-13  
 development of, 103e-5–6, 103e-6f  
 dose-limiting toxicity, 103e-5  
 gene therapy to enhance, 91e-3–4  
 high-dose regimens, 103e-7, 103e-8t  
 intraperitoneal, 593  
 late complications of, 620t  
   cardiovascular, 270e-21–22, 621, 1562–1563  
   hematologic, 678  
   hepatic, 622  
   neurologic, 622  
   ocular, 623  
   pulmonary, 621–622  
   Raynaud's phenomenon, 623  
   renal/urinary, 622–623  
   reproductive/endocrine, 623, 2365  
   maximum-tolerated dose, 103e-5  
   metabolism modulators for, 102e-13  
   nausea and vomiting in. *See* Nausea and vomiting, chemotherapy-induced  
   neoadjuvant, 103e-7  
   palliative, 103e-7, 103e-8t  
   partial response to, 103e-5  
   during pregnancy, 103e-26, 124e-1, 124e-2  
   principles for use, 103e-5–8  
   resistance to, 102e-12, 103e-23  
   response to, 103e-5–6  
   supportive care during, **103e-23**  
     alopecia, 103e-25  
     diarrhea, 103e-25  
     gonadal dysfunction, 103e-25–26  
     mucositis, 103e-25  
     myelosuppression, 103e-23–25, 103e-24t  
     nausea and vomiting. *See* Nausea and vomiting, chemotherapy-induced  
     targeted, 102e-5t, **103e-15**, 103e-17–19t  
     action of, 103e-3–4, 103e-5t, 103e-6, 103e-7f, 103e-16f  
     adverse effects of, 103e-25–26  
     arsenic trioxide, 103e-19t  
     combination, 102e-4, 102e-6  
     development of, 103e-6  
     diagnostically guided, 101e-8–9, 103e-16, 103e-17t  
     DNA methyltransferase inhibitors, 102e-8, 102e-8f, 103e-20  
     histone deacetylase inhibitors, 102e-7–8, 102e-8f, 103e-18t, 103e-19–20  
     hormone receptor-directed, 102e-7, 103e-5, 103e-15–16  
     mTOR inhibitors, 102e-3, 103e-18t  
     multikinase inhibitors, 102e-3–4, 102e-4f, 103e-18t, 103e-19  
     nondiagnostically guided, 103e-17t  
     principles of, 103e-5  
     proteasome inhibitors, 102e-6, 102e-9f, 103e-18t, 103e-19  
     vismodegib, 102e-5t, 103e-19t  
     timing of, 194  
 Cancer genetics, **101e-1. See also specific cancers**  
 cancer gene classes, 101e-1–2. *See also* Oncogene(s); Tumor-suppressor genes  
 chromosomal instability in solid tumors, 101e-3–4  
 clonal origin and multistep nature of cancer, 101e-1, 101e-1f